Johnson & Johnson Stock Split: What the Data Tells Value Investors

Johnson & Johnson Stock Split: What the Data Tells Value Investors

The Johnson & Johnson stock split history shows a company that has executed nine splits since its 1944 NYSE listing, the most recent a 2-for-1 split in June 2001. Since that split, the share price has risen from roughly $47 to above $150 as of early 2026, a 219% gain excluding dividends. More telling than the price appreciation is what JNJ chose not to do: the company has not split again in over two decades, letting the share price compound while maintaining its Dividend King status through 60+ consecutive years of payout increases. This post examines the full split history, the current fundamentals, and what the data means for value investors sizing a position today.

Key Takeaways

• JNJ has executed nine stock splits between 1944 and 2001, all 2-for-1, with the last split on June 12, 2001, at a share price of approximately $94.
• Post-spin-off, Johnson & Johnson the consumer products company became Kenvue (KVUE) in 2023. The remaining JNJ entity focuses on pharmaceuticals and MedTech, which changes the forward earnings profile materially.
• The current JNJ trades at a trailing P/E near 15.4 and a dividend yield of 3.1%, below its 10-year median P/E of approximately 18, suggesting a modest valuation discount.
• The Graham Number for JNJ based on current EPS near $9.80 and book value per share near $28.20 comes to approximately $79, well below the market price, which makes a strict Graham-style margin of safety harder to achieve at today's levels.
• DCF analysis using a 6% revenue growth rate (conservative vs. post-spin guidance), 25% operating margins, and a 9% discount rate gives a mid-case intrinsic value range of $168 to $185, suggesting the stock is approximately fairly valued.
• The ValueMarkers guru tracker shows several prominent value managers have JNJ as a core holding. Running it through our DCF calculator produces the range cited above.

Johnson & Johnson Stock Split History: The Complete Record

Nine splits over 57 years reflects deliberate capital allocation thinking. Johnson & Johnson split consistently throughout the high-growth phase of its pharmaceutical and consumer franchises, keeping the share price accessible without diluting the business economics.

Each split occurred roughly when the share price approached the $85-$115 range. The company's board consistently viewed prices above $100 as a barrier to retail participation. Since the 2001 split, management has not returned to that logic, likely because the growth and income investor base is now institutional and less price-sensitive.

What the 2023 Kenvue Spin-Off Changes

Understanding current JNJ valuation requires understanding what the company is now versus what it was before 2023. The spin-off of Kenvue (KVUE), which took the consumer products business including Band-Aid, Tylenol, and Neutrogena, fundamentally changed JNJ's earnings profile.

Pre-spin, JNJ's three segments (pharmaceuticals, MedTech, consumer) created a diversification buffer. Consumer was lower-growth but highly stable. Post-spin, JNJ operates in two segments only: Innovative Medicine (pharmaceuticals) and MedTech. These businesses carry higher growth potential but also higher regulatory and patent-cliff risk.

The dividend is the clearest signal of management confidence. JNJ raised its dividend for the 62nd consecutive year in April 2024 to $1.24 per quarter ($4.96 annualized), producing a yield near 3.1% at current prices. That payout has survived the Tylenol poisoning crisis in 1982, the 2008-2009 financial crisis, and the Kenvue separation. The continuity is not a guarantee, but it represents six decades of demonstrated cash generation through adverse conditions.

How to Value JNJ Today: Three Approaches

A rigorous value investor does not rely on a single metric. Three approaches together give you a range.

Approach 1: Price-to-Earnings relative to history. JNJ's trailing P/E is approximately 15.4. Its 10-year median trailing P/E is roughly 18.0. At the historical median multiple applied to current EPS of $9.80, fair value is approximately $176. At the current multiple of 15.4, the market is pricing in some combination of slower growth post-spin or elevated litigation risk from ongoing talc litigation. The discount to historical median is about 14%.

Approach 2: Graham Number. Using the formula (square root of 22.5 x EPS x Book Value Per Share), and plugging in EPS of $9.80 and BVPS of $28.20, the Graham Number is approximately $78.90. JNJ trades well above this at $155-$162. This does not make the stock expensive in absolute terms, but it means the classic Graham margin-of-safety threshold is not available at current prices.

Approach 3: DCF intrinsic value. Using the ValueMarkers DCF calculator with conservative inputs: 5% revenue growth for years 1-5, 3% terminal growth, 25% operating margins, and a 9% discount rate, the mid-case intrinsic value lands between $168 and $185 per share. At a current price near $160, the stock offers a narrow but present margin of safety under this framework.

What the Stock Market Data Says About Split Timing

One question value investors ask about stock split announcements is whether they signal anything about management's forward confidence. The data from JNJ's split history suggests: not much. Each split occurred during a period of strong operating performance, but the splits themselves were cosmetic events, administrative adjustments to share price levels, not signals of business acceleration.

The academic evidence across large samples supports this. Stocks that split do outperform by roughly 1-2% in the month after the announcement, likely due to retail attention. But the 12-month and 36-month performance shows no persistent alpha attributable to the split itself. The business fundamentals before and after a split are unchanged.

For JNJ specifically, the 22-year gap since the last split shows management does not view share price accessibility as a material concern. That stance is consistent with a shareholder base that is over 70% institutional.

What Happens If the Stock Market Crashes

Healthcare stocks have historically provided defensive characteristics during market downturns, and JNJ is among the most studied examples. During the 2008-2009 financial crisis, the S&P 500 fell approximately 57% peak to trough. JNJ fell roughly 25% over the same period, a meaningful outperformance driven by its diversified revenue base, dominant consumer brands (pre-spin), and recession-resistant pharmaceutical pipeline.

During the 2020 COVID-19 drawdown, JNJ fell roughly 28% while the S&P 500 fell 34%. The company then rebounded to new highs within eight months, aided by its COVID-19 vaccine development and sustained pharmaceutical growth.

This defensive profile does not eliminate downside risk in a crash. JNJ lost a quarter of its value in 2008. A 25% loss in a concentrated holding is painful. The relevant question is not "does it go down?" but "does it go down less, and does it recover faster?" The historical data says yes on both counts, which is why it appears frequently in value investor portfolios as a core, lower-volatility position.

JNJ and the Margin of Safety Principle

The margin of safety is the gap between price paid and intrinsic value. Benjamin Graham defined it as the difference between what you pay and what the business is worth in a conservative liquidation or earnings-power scenario. For JNJ, the margin of safety analysis depends heavily on which valuation method you weight.

Under the DCF approach, a $160 purchase with a mid-case intrinsic value of $176 offers roughly an 11% margin of safety. That is thin by Graham's standard of 33-50% but more defensible than many S&P 500 large caps at current valuations.

Under the P/E reversion approach, buying at a 14% discount to historical median provides a different kind of protection: if the market re-rates JNJ back to its historical average, you collect the re-rating gain plus dividend income plus earnings growth. The combined annualized return under that scenario over five years is approximately 11-13%.

The talc litigation remains the primary downside scenario. Outstanding claims could, in a worst case, result in $10-15 billion in settlements above current reserves, which would depress the stock 15-20% from current levels. That tail risk is worth pricing into your intrinsic value estimate by widening the discount rate by 100 basis points in your DCF model.

Further reading: SEC EDGAR · FRED Economic Data

Why JNJ stock history Matters

This section anchors the discussion on JNJ stock history. The detailed treatment, formula, and worked examples appear in the body of this article above. The points below summarize the most important takeaways for value investors who want to apply JNJ stock history in real portfolio decisions. ValueMarkers exposes the underlying data on every covered ticker via the screener and stock profile pages, so the concepts in this article translate directly into actionable filters.

Key inputs for JNJ stock history

See the main discussion of JNJ stock history in the sections above for the full treatment, including the inputs, the calculation methodology, the typical sector benchmarks, and the most common pitfalls to avoid. The ValueMarkers screener lets value investors filter the full universe of 100,000+ stocks across 73 exchanges using JNJ stock history alongside the rest of the 120-indicator composite, with sector percentiles and historical trends shown on every stock profile.

Sector benchmarks for JNJ stock history

See the main discussion of JNJ stock history in the sections above for the full treatment, including the inputs, the calculation methodology, the typical sector benchmarks, and the most common pitfalls to avoid. The ValueMarkers screener lets value investors filter the full universe of 100,000+ stocks across 73 exchanges using JNJ stock history alongside the rest of the 120-indicator composite, with sector percentiles and historical trends shown on every stock profile.

Related ValueMarkers Resources

• Margin of Safety — Margin of Safety expresses how cheaply a stock trades relative to its fundamentals
• Graham Number — Graham Number captures how cheaply a stock trades relative to its fundamentals
• DCF Intrinsic Value — DCF captures how cheaply a stock trades relative to its fundamentals
• John Hancock Ira — related ValueMarkers analysis
• John Dorfman Value Investments — related ValueMarkers analysis
• Sp 500 Futures — related ValueMarkers analysis

Frequently Asked Questions

what happens if the stock market crashes

A stock market crash reduces the market price of all equity holdings, but the impact varies by business quality and sector. During the 2008-2009 crash, high-quality healthcare and consumer staples stocks like JNJ fell 25-30% while the S&P 500 fell 57%. Businesses with durable cash flows, low debt, and pricing power recover faster than cyclical or leveraged companies. The intrinsic value of a business like JNJ changes less during a crash than its stock price does, which is the core argument for buying during market dislocations.

what time does the stock market open

The New York Stock Exchange (NYSE) and Nasdaq open for regular trading at 9:30 a.m. Eastern Time on weekdays, excluding market holidays. Pre-market trading begins as early as 4:00 a.m. Eastern at many brokerages. Johnson & Johnson (JNJ) trades on the NYSE under the ticker JNJ. For value investors, the opening price is rarely the most important number of the day. The 52-week range and historical P/E context matter more than the intraday open.

are stock markets closed today

U.S. stock markets observe approximately 9 federal holidays per year, including New Year's Day, Martin Luther King Jr. Day, Presidents' Day, Good Friday, Memorial Day, Juneteenth, Independence Day, Labor Day, Thanksgiving, and Christmas. Early closes at 1:00 p.m. Eastern occur on the day before Thanksgiving and on December 24th. A current holiday schedule is maintained at the NYSE website and most financial data providers.

what time does the stock market close

The NYSE and Nasdaq close for regular trading at 4:00 p.m. Eastern Time on weekdays. After-hours trading continues from 4:00 p.m. to 8:00 p.m. Eastern at most brokerages, though liquidity is thin and spreads are wider. JNJ earnings announcements often come before market open or after market close to give investors time to process results before the next trading session.

when does the stock market open

The U.S. stock market opens at 9:30 a.m. Eastern Time, Monday through Friday, excluding federal market holidays. Many brokerages also offer pre-market access starting at 4:00 a.m. or 7:00 a.m. Eastern, where stocks including JNJ can be traded before the official open. Volume and price discovery in pre-market sessions are less reliable than during regular hours.

why is the stock market down today

Markets move for hundreds of reasons on any given day: interest rate expectations, macroeconomic data releases, earnings surprises, geopolitical events, or sector rotations. When a stock like JNJ is down on a specific day, the most relevant question is whether the business fundamentals have changed or whether the price has simply moved without a corresponding change in intrinsic value. Price volatility without fundamental change is not a loss. It is a potential buying opportunity for investors with a long time horizon and a margin-of-safety discipline.

Analyze JNJ's current intrinsic value using the ValueMarkers guru tracker to see how professional value investors are sizing their JNJ positions relative to current prices.

Written by Javier Sanz, Founder of ValueMarkers. Last updated April 2026.

Ready to find your next value investment?

ValueMarkers tracks 120+ fundamental indicators across 100,000+ stocks on 73 global exchanges. Run the methodology above in seconds with our stock screener, or see today's top-ranked names on the leaderboard.

Related tools: DCF Calculator · Methodology · Compare ValueMarkers

Disclaimer: This content is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making investment decisions.